Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICX-RHY
- Development stage
- Discontinued
- Lead developer
- Ember Therapeutics
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intradermal
01
Overview
ICX-RHY is an autologous cell therapy developed by Intercytex for the treatment of facial wrinkles (rhytids) and depressed scars. The product consists of a suspension of the patient's own dermal fibroblasts, which are harvested via a small skin biopsy, expanded in vitro in a specialized manufacturing facility, and then reinjected into the patient's dermis. The mechanism of action involves the direct delivery of active, functional fibroblasts to the site of skin aging or injury. These cells are responsible for the production of essential extracellular matrix components, including Type I and Type III collagen, elastin, and glycosaminoglycans, which restore skin structure, elasticity, and volume. By replenishing the fibroblast population, ICX-RHY aims to reverse the thinning of the dermis associated with aging and promote biological tissue regeneration. Development of the candidate was halted following the financial restructuring and administration of Intercytex in 2009.
- Brand names
- Vavelta
- Other names
- autologous dermal fibroblasts
Beyond the preview
Go deeper on ICX-RHY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICX-RHY.